open access
Radiopharmaceutical for detecting PSMA — positive metastatic colon cancer: Matched-pair comparison of 18F-BF3-Cy3-ACUPA and 68Ga-PSMA PET/MRI
, 2, 3, 3, 4
Affiliations- Departament of Radiology, Memorial Sloan Kettering Cancer Center, New York, United States
- Department of Urology, Cerrahpasa Medical Faculty, Istanbul, Turkey
- Department of Radiology, Weill Cornell Medicine, New York, United States
- Department of Nuclear Medicine, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul,Turkey
open access
Abstract
Prostate-specific membrane antigen (PSMA) — based radiopharmaceuticals are promising for the evaluation of PSMA-positive non-prostate cancers. In this case study, 18F-BF3-Cy3-ACUPA and 68Ga-PSMA positron emission tomography/magnetic resonance imaging (PET/MRI) were compared in a patient with metastatic colon cancer. Both 18F-BF3-Cy3-ACUPA and 68Ga-PSMA PET/MRI showed biopsy-proven metastatic left external iliac adenopathy, highlighting the feasibility of PSMA uptake in PET/MRI of metastatic nodal disease from colon cancer. Along with imaging evaluation, PSMA-based radiopharmaceuticals may also be used as a surrogate imaging tracer for potential theranostic applications using alpha or beta emitters in the context of PSMA-directed radiopharmaceutical therapy in advanced and progressive colorectal cancer.
Abstract
Prostate-specific membrane antigen (PSMA) — based radiopharmaceuticals are promising for the evaluation of PSMA-positive non-prostate cancers. In this case study, 18F-BF3-Cy3-ACUPA and 68Ga-PSMA positron emission tomography/magnetic resonance imaging (PET/MRI) were compared in a patient with metastatic colon cancer. Both 18F-BF3-Cy3-ACUPA and 68Ga-PSMA PET/MRI showed biopsy-proven metastatic left external iliac adenopathy, highlighting the feasibility of PSMA uptake in PET/MRI of metastatic nodal disease from colon cancer. Along with imaging evaluation, PSMA-based radiopharmaceuticals may also be used as a surrogate imaging tracer for potential theranostic applications using alpha or beta emitters in the context of PSMA-directed radiopharmaceutical therapy in advanced and progressive colorectal cancer.
Keywords
18F-BF3-Cy3-ACUPA; 68Ga-PSMA; colorectal cancer; PET/MRI; PSMA
About this articleTitle
Radiopharmaceutical for detecting PSMA — positive metastatic colon cancer: Matched-pair comparison of 18F-BF3-Cy3-ACUPA and 68Ga-PSMA PET/MRI
Journal
Issue
Article type
Clinical vignette
Pages
129-130
Published online
2022-06-09
Page views
4719
Article views/downloads
525
DOI
Pubmed
Bibliographic record
Nucl. Med. Rev 2022;25(2):129-130.
Keywords
18F-BF3-Cy3-ACUPA
68Ga-PSMA
colorectal cancer
PET/MRI
PSMA
Authors
Omer Aras
Cetin Demirdag
Harikrishna Kommidi
Richard Ting
Haluk B. Sayman
References (5)- Aras O, Demirdag C, Kommidi H, et al. Simultaneous injection of 18 F-BF3- Cy3-ACUPA and non-radioactive Cy7-ACUPA probes: a promising pre-biopsy PET and ex vivo fluorescence imaging approach to evaluate prostate cancer . Eur J Nucl Med Mol Imaging. 2021; 48(11): 3732–3733.
- Hangaard L, Jochumsen MR, Vendelbo MH, et al. Metastases From Colorectal Cancer Avid on 68Ga-PSMA PET/CT. Clin Nucl Med. 2017; 42(7): 532–533.
- Huang YTT, Fong W, Thomas P. Rectal Carcinoma on 68Ga-PSMA PET/CT. Clin Nucl Med. 2016; 41(3): e167–e168.
- Cuda TJ, Riddell AD, Liu C, et al. PET Imaging Quantifying Ga-PSMA-11 Uptake in Metastatic Colorectal Cancer. J Nucl Med. 2020; 61(11): 1576–1579.
- Salas Fragomeni RA, Amir T, Sheikhbahaei S, et al. Imaging of Nonprostate Cancers Using PSMA-Targeted Radiotracers: Rationale, Current State of the Field, and a Call to Arms. J Nucl Med. 2018; 59(6): 871–877.
